Jane Street Group LLC Boosts Stake in Fractyl Health, Inc. (NASDAQ:GUTS)

Jane Street Group LLC lifted its position in shares of Fractyl Health, Inc. (NASDAQ:GUTS) by 125.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,700 shares of the company’s stock after acquiring an additional 12,648 shares during the quarter. Jane Street Group LLC’s holdings in Fractyl Health were worth $47,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Rhumbline Advisers boosted its stake in shares of Fractyl Health by 73.1% during the 4th quarter. Rhumbline Advisers now owns 25,626 shares of the company’s stock worth $53,000 after acquiring an additional 10,826 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Fractyl Health during the 4th quarter worth about $34,000. Norges Bank acquired a new position in shares of Fractyl Health during the 4th quarter worth about $206,000. Bank of New York Mellon Corp raised its position in shares of Fractyl Health by 27.3% during the 4th quarter. Bank of New York Mellon Corp now owns 41,448 shares of the company’s stock worth $85,000 after purchasing an additional 8,886 shares during the last quarter. Finally, HighTower Advisors LLC raised its position in shares of Fractyl Health by 72.8% during the 4th quarter. HighTower Advisors LLC now owns 25,921 shares of the company’s stock worth $53,000 after purchasing an additional 10,921 shares during the last quarter.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group assumed coverage on shares of Fractyl Health in a research report on Tuesday, April 15th. They set a “buy” rating and a $12.00 price target for the company.

Fractyl Health Stock Up 44.7%

GUTS opened at $2.88 on Tuesday. Fractyl Health, Inc. has a twelve month low of $0.87 and a twelve month high of $6.54. The company has a quick ratio of 5.57, a current ratio of 5.58 and a debt-to-equity ratio of 0.60. The company has a 50-day moving average price of $1.52 and a 200 day moving average price of $1.68. The company has a market cap of $141.05 million, a PE ratio of -0.24 and a beta of 1.85.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.49) earnings per share for the quarter, hitting the consensus estimate of ($0.49). Sell-side analysts expect that Fractyl Health, Inc. will post -1.61 earnings per share for the current fiscal year.

Fractyl Health Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.